This month’s announcements of awards, expansions, name changes, hires, and other news includes items from CPhI, Almac Group, ICON, and other organizations.
The company has received a $500,000 grant from the COVID-19 Therapeutics Accelerator to develop manufacturing processes for the antiviral drug remdesivir.
The company’s annual survey of pharmaceutical and biotechnology leaders reveals their needs, plans and concerns for the immediate and long-term future.
Almac joins a working group made up of clinical supply chain industry members, in order to contribute to the use case discussion about blockchain technology.
Almac announced it has increased its supply of neo-antigen peptides for individualized cancer treatments with the addition of another stream of GMP manufacturing.
Almac has opened a new 24,000 square foot building at its location in Durham, NC to meet demand driven by the rise in biological investigational products, says CDMO.
Almac Group’s acquisition of BioClin Laboratories expands the company’s analytical services – a growing area of business due to increasing global client requirements, says CDMO.
Northern Ireland-based Almac Group has launched its selectAZyme brand, which provides a wide range of enzymes such as reductases, hydrolases, nitrolases for manufacturing applications.
